Premium
Fibroblast growth factor receptor‐1 as a potential therapeutic target in sinonasal cancer
Author(s) -
Schröck Andreas,
Göke Friederike,
Wagner Patrick,
Bode Maike,
Franzen Alina,
Huss Sebastian,
Agaimy Abbas,
Ihrler Stephan,
Kirsten Robert,
Kristiansen Glen,
Bootz Friedrich,
Lengerke Claudia,
Perner Sven
Publication year - 2014
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23443
Subject(s) - fibroblast growth factor receptor 1 , fluorescence in situ hybridization , adenoid cystic carcinoma , medicine , pathology , cancer , cancer research , lymph node , adenocarcinoma , esthesioneuroblastoma , carcinoma , oncology , biology , fibroblast growth factor , receptor , radiation therapy , gene , biochemistry , chromosome
Background Despite multimodal treatment, sinonasal malignancies have an unfavorable prognosis. The purpose of this study was to elucidate if these tumors harbor amplifications of the fibroblast growth factor receptor 1 ( FGFR1 ) gene, which has recently been identified as a potential therapeutic target in squamous cell lung cancer. Methods One hundred twelve primary tumors (including squamous cell carcinoma [SCC], carcinoma associated with an inverted papilloma, sinonasal undifferentiated carcinoma [SNUC], adenocarcinoma, adenoid cystic carcinoma [ACC], esthesioneuroblastoma, and 9 corresponding lymph node metastases) were assessed by fluorescence in situ hybridization (FISH) for FGFR1 copy number status. Human papillomavirus (HPV) status was assessed by p16 immunohistochemical as a surrogate marker. Results FGFR1 amplification was found in subsets of sinonasal SCCs (20%), carcinomas associated with an inverted papilloma (33%), and SNUCs (5%). In all cases, metastatic tumor samples shared the same FGFR1 amplification status as the corresponding primary tumor tissue. None of the FGFR1 ‐amplified tumors expressed p16. Conclusion FGFR1 amplification represents a potential molecular target in a subset of patients with sinonasal cancer. © 2014 Wiley Periodicals, Inc. Head Neck 36: 1253–1257, 2014